Trial Profile
Phase III, double-blind trial of lasofoxifene in postmenopausal with low or normal bone mineral density
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2016
Price :
$35
*
At a glance
- Drugs Lasofoxifene (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacodynamics
- Acronyms OPAL
- 18 Sep 2015 New trial record
- 16 Sep 2015 Results will be presented at the North American Menopause Society (NAMS) Annual Meeting 2015, according to a Sermonix Pharmaceuticals media release.